Heron Therapeutics, Inc. re-affirmed earnings guidance for the full year 2024. For the period, Company expects Net Product Revenues of $138.0 million to $158.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.77 USD | +1.09% | -16.82% | +62.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.94% | 413M | |
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024